Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Glenmark Pharma to Hive Off Generics Biz (India)

This article was originally published in PharmAsia News

Executive Summary

Glenmark Pharmaceuticals reports it will spin off its generics business to new company Glenmark Generics (GGL). GGL will handle the development, manufacture and marketing of generic formulation and API businesses, and will be a wholly-owned subsidiary of Glenmark Pharmaceuticals. Glenmark Pharmaceuticals will continue to directly manage the novel R&D and branded formulation businesses of the group. Terrance Coughlin, currently president of Glenmark Pharmaceuticals, will take over as CEO of Glenmark Generics. Glenn Saldanha, CEO of Glenmark Pharmaceuticals, will be the chairman of the new company. "Both our specialty and generics businesses have now grown immensely, posing a growth challenge of managing two large but diverse businesses," Saldanha says. "The sheer size of the business now has its own set of management challenges. To address these challenges, strengthen our focus on R&D and accelerate our growth in the generics and API business, we are happy to announce a plan to reorganize our businesses by moving the generics and API businesses into a wholly-owned subsidiary." (Click here for more

You may also be interested in...

Coronavirus Update: After UK Nod, New Forecast Makes Pfizer Vaccine The Leader

After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer's COVID-19 vaccine in 2021 and beyond.

Compare And Contrast: New UKCA Marking System Will Stress Safety, Quality and Agility

How UK and EU device regulations will differ in 2021, UK approved bodies and Northern Ireland's unfettered access to the UK market were key themes at the ABHI’s annual regulatory conference.

China Preps For First COVID Vaccine Roll-Outs

Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts